Articles related to CARDIOVASCULAR EVENTS

Bempedoic acid reduced major adverse cardiovascular events by 13% compared to placebo in statin-intolerant patients, with efficacy comparable to statins when normalized for LDL-C reduction.

The ABYSS trial questions the safety of interrupting long-term beta-blocker treatment in patients with a history of uncomplicated myocardial infarction, finding that discontinuation was not noninferior to continuation.

Extraosseous calcification in chronic and end-stage kidney disease involves a complex pathogenesis, impacting patient morbidity and mortality through vascular, soft tissue, and calciphylaxis manifestations.

Recent findings indicate that statin-naïve ACS patients with normal LDL-C levels at admission may face worse outcomes, challenging current perspectives on lipid management in cardiovascular care.

Rapid optimization of guideline-directed medical therapy in heart failure patients post-discharge was associated with sustained decongestion and improved clinical outcomes at 90 days.

Women’s heart attack symptoms often differ significantly from men’s, presenting as subtle signs that can be easily overlooked or misattributed to other conditions.